-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Immix Biopharma, Lowers Price Target to $22

Benzinga·11/18/2026 15:24:06
Listen to the news
Mizuho analyst Graig Suvannavejh maintains Immix Biopharma (NASDAQ:IMMX) with a Outperform and lowers the price target from $23 to $22.